Otsuka Busulfex's Overall Survival Claim Does Not Survive CDER Advertising Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
Statistical analyses based on pivotal trial data and used to promote a drug must prove what they purport to prove, FDA's Office of Prescription Drug Promotion says in an NOV letter to Otsuka over a website for the leukemia drug Busulfex (busulfan).
You may also be interested in...
Efficacy Overstatements In Evofem’s Phexxi Brochure, Otsuka’s Rexulti TV Ad Draw Untitled Letters
US FDA releases two letters on the same day citing two different kinds of advisements for two different kinds of products, but both with a classic problem: overstatement of efficacy. And while sending multiple letters at once can be seen as bid to draw attention to its enforcement action, the move also underscores just how few letters the agency has been sending lately.
FDA Turns Off Otsuka’s Abilify Dimmer Switch Graphic
As lights go out on the franchise, FDA says pharmacology aid misleadingly suggests Abilify offers advantages over other treatments.
FDA Cites Gleevec For Promoting Unapproved Indications Three Weeks Before Expanding Label
Notice of violation letter to Novartis from FDA’s Office of Prescription Drug Promotion expresses concern about describing a patient with five-year survival data, a claim that was added to the label the following month.